Key facts
- It has raised $2.8M; the latest was Early Stage VC in Dec 2024.
- Notable investors include Shunde Group, Grand Capital ().
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Wankesen Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Wankesen Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Wankesen Biotechnology
Manufacturer of advanced subunit and immersion administered biological immunizations intended for marine aquaculture vaccines. The company offers immersion-based nanocarrier vaccine formulations rooted in gene-engineered subunit antigen technology, polymer-supported delivery systems, and targeted release platforms, enabling aquaculture producers and hatcheries to improve herd-level health and sustainable biosecurity across diverse aquatic environments.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2019
- Website
- vancsen.com/
- Ownership
- Privately Held (backing)
Wankesen Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Wankesen Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Wankesen Biotechnology in its N-PORT filings yet. We sweep new filings monthly.